Study:
Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension
Rationale:
n/a
Purpose:
Patients with advanced sarcoidosis often develop pulmonary hypertension. Pulmonary
hypertension is a condition where the right side of the heart has to push the blood though
the lungs at a higher pressure than normal. Since this pressure is higher, it is harder for
the heart to pump the blood through the lungs to the left side of the body. If the blood can
not get through the lungs, it can not get pumped through the rest of the body. This leads to
weakness and shortness of breath. This type of hypertension does not usually respond to
regular blood pressure medicines. The purpose of this study is to determine if bosentan
(Tracleer) will help sarcoidosis associated pulmonary hypertension.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Sarcoidosis
Pulmonary Arterial Hypertension |
Drug: Bosentan
Drug: Placebo
Drug: Bosentan
Drug: Placebo |
Phase 2/Phase 3 |
Verified by
University of Cincinnati
April, 2013
Sponsored by: University of Cincinnati
Information provided by: University of Cincinnati
ClinicalTrials.gov identifier: NCT00581607
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Cleveland Clinic
Cleveland, Ohio
United States
Robert P Baughman, MD., Principal Investigator